Frequent episodes of acute renal failure and a complication of Fanconi's syndrome in a patient with paroxysmal nocturnal hemoglobinuria

1997 ◽  
Vol 1 (2) ◽  
pp. 151-156
Author(s):  
Junichiro Mera ◽  
Shunya Uchida ◽  
Michitaka Fujimaki ◽  
Katsuyuki Matsui ◽  
Suechika Suzuki ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Paroxysmal Nocturnal Hemoglobinuria ◽  
Fanconi’S Syndrome ◽  
Frequent Episodes ◽  
Fanconi's Syndrome

scholarly journals Hemolysis-Induced Acute Renal Failure in Paroxysmal Nocturnal Hemoglobinuria

Nephron ◽  
1994 ◽  
Vol 66 (1) ◽  
pp. 112-112 ◽  
Author(s):  
Aliza Zeidman ◽  
Avry Chagnac ◽  
Meyer Wisnovitz ◽  
Moshe Mittelman
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Paroxysmal Nocturnal Hemoglobinuria

Osteomalacia due to Fanconi’s syndrome and renal failure caused by long-term low-dose adefovir dipivoxil

2012 ◽  
Vol 17 (1) ◽  
pp. 147-148 ◽  
Author(s):  
Homare Shimohata ◽  
Shinsuke Sakai ◽  
Yujiro Ogawa ◽  
Kouichi Hirayama ◽  
Masaki Kobayashi
Keyword(s):  
Renal Failure ◽  
Adefovir Dipivoxil ◽  
Low Dose ◽  
Fanconi’S Syndrome ◽  
Fanconi's Syndrome

scholarly journals Hemodialysis treatment for acute renal failure accompanied by paroxysmal nocturnal hemoglobinuria.

1994 ◽  
Vol 27 (9) ◽  
pp. 1215-1221
Author(s):  
Yoshihisa Yamaguchi ◽  
Yuichiro Yasumoto ◽  
Kenichi Takenouchi ◽  
Mayumi Fukumoto ◽  
Yoshio Uchida ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Paroxysmal Nocturnal Hemoglobinuria ◽  
Hemodialysis Treatment

Two Cases of Acute Renal Failure Complicating Paroxysmal Nocturnal Hemoglobinuria in Children

2008 ◽  
Vol 12 (2) ◽  
pp. 221
Author(s):  
Jung Min Ryu ◽  
Yohan Ahn ◽  
Sohee Lee ◽  
Hyun Jin Choi ◽  
Beom Hee Lee ◽  
...  
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Paroxysmal Nocturnal Hemoglobinuria

Fanconi's syndrome and subsequent progressive renal failure caused by a Chinese herb containing aristolochic acid

Nephrology ◽  
2004 ◽  
Vol 9 (3) ◽  
pp. 126-129 ◽  
Author(s):  
SANGHO LEE ◽  
TAEWON LEE ◽  
BYUNGCHEOL LEE ◽  
HYUCKJAI CHOI ◽  
MUNHO YANG ◽  
...  
Keyword(s):  
Renal Failure ◽  
Aristolochic Acid ◽  
Chinese Herb ◽  
Progressive Renal Failure ◽  
Fanconi’S Syndrome ◽  
Fanconi's Syndrome

scholarly journals Paroxysmal nocturnal hemoglobinuria: rare cause of acute renal failure

2012 ◽  
Vol 2 (4) ◽  
pp. 61-64
Author(s):  
Vilma Takayasu ◽  
Márcia Yoshie Kanegae ◽  
Jairo Rays
Keyword(s):  
Renal Failure ◽  
Acute Renal Failure ◽  
Paroxysmal Nocturnal Hemoglobinuria

scholarly journals Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 2227-2227
Author(s):  
Ka-Won Kang ◽  
Hyemi Moon ◽  
Byung-Hyun Lee ◽  
Min Ji Jeon ◽  
Eun Sang Yu ◽  
...  
Keyword(s):  
Renal Failure ◽  
Pulmonary Hypertension ◽  
Acute Renal Failure ◽  
Health Insurance ◽  
Survival Rate ◽  
South Korea ◽  
Real World ◽  
Arterial Thrombosis ◽  
Paroxysmal Nocturnal Hemoglobinuria ◽  
Treated Group

Purpose Eculizumab is reported to be highly effective in managing patients with paroxysmal nocturnal hemoglobinuria (PNH). However, eculizumab therapy is associated with high cost and thus is inaccessible to all patients with PNH. Additionally, there are some restrictions in the coverage of PNH therapy from the health insurance, which varies depending on each country. In South Korea, majority of the cost involved in eculizumab therapy is supported by the National Health Insurance Service (NHIS) with very limited indication. The patients with PNH must satisfy all of the following criteria to be eligible for financial support from NIHS: (1) PNH granulocyte count ≥ 10%; (2) lactate dehydrogenase ≥ 1.5 times the upper limit of normal; (3) at least 4 units of red blood cells must have be transfused in the past 12 months (transfusion-dependent anemia (TDA)); and (4) exhibit at least more than one of the PNH-related complications (except TDA), which include thrombosis, renal insufficiency, pulmonary insufficiency, or recurrent smooth muscle spasm. These criteria are the narrowest indication for eculizumab therapy compared with those used by other countries. Hence, we performed a nation-wide study including all the patients with PNH in South Korea using the NHIS database to investigate the real-world efficacy of eculizumab. Methods The National Health Insurance Database of the NHIS in South Korea was used to collect the data of patients diagnosed with PNH between January 1, 2002 and December 31, 2016. Propensity score (PS) method was used to evaluate the real-world effects of eculizumab on patient survival. For PS method, the patients with PNH were divided into the following two groups: (1) patients treated with eculizumab; and (2) patients not treated with eculizumab. Additionally, the patients used for the analysis were limited to those who are surviving from the time of introduction of eculizumab in South Korea (October 1, 2012). In total, 11 variables were selected for PS matching according to the indications for using eculizumab in South Korea: age, sex, TDA, venous thrombosis, arterial thrombosis, AA, MDS, acute renal failure (ARF), chronic renal failure (CRF), prescription of opioid analgesic drug (≥ 2 times), and pulmonary hypertension. The patients diagnosed with acute leukemia were excluded. The time point of the matching was designated as the date on which the eculizumab was first administered. All survival or complication analyses were performed using the Cox proportional hazard regression model. The duration of PNH was used as the explanatory variable to estimate the proper treatment effect. Results Eculizumab-treated patients exhibited significantly higher survival rate than the eculizumab-untreated patients (4-year survival after propensity score matching, 98.31% vs. 79.67%, p = 0.0489). The mean RBC transfusion units per 12 months after eculizumab therapy was significantly lower than that before eculizumab therapy (5.75 units vs. 12.28 units, p < 0.0001). The median time for the first transfusion in the eculizumab-treated group was significantly longer than that in the eculizumab-untreated group (p = 0.0078). The 4-year transfusion-independence rate for the eculizumab-treated group was significantly higher than that for the eculizumab-untreated group (20.81%; 95% CI, 10.71-33.20%, vs. 10.24%; 95% CI, 4.17-19.50%). There was no significant difference in the incidence of new documented complications related to PNH between the two groups. These complications include venous thrombosis (p = 0.886), arterial thrombosis (p = 0.112), acute renal failure (p = 0.745), chronic renal failure (p = 0.827), use of opioid analgesics (p = 0.142), and pulmonary hypertension (p = 0.396). Conclusions Eculizumab therapy for high-risk PNH patients may effectively improve the survival rate and reduce the transfusion requirement. Paradoxically, the eculizumab-treated patients with severe PNH exhibit higher survival rate than the eculizumab-untreated patients with less severe PNH. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document